OBJECTIVE: Multicenter longitudinal outcome data for Fontan patients surviving into adulthood are lacking. The aim of this study was to better understand contemporary outcomes in Fontan survivors by collecting follow-up data in a previously well-characterized cohort. DESIGN: Baseline data from the Fontan Cross-Sectional Study (Fontan 1) were previously obtained in 546 Fontan survivors aged 11.9 ± 3.4 years. We assessed current transplant-free survival status in all subjects 6.8 ± 0.4 years after the Fontan 1 study. Anatomic, clinical, and surgical data were collected along with socioeconomic status and access to health care. RESULTS: Thirty subjects (5%) died or underwent transplantation since Fontan 1. Subjects with both an elevated (>21 pg/mL) brain natriuretic peptide and a low Child Health Questionnaire physical summary score (<44) measured at Fontan 1 were significantly more likely to die or undergo transplant than the remainder, with a hazard ratio of 6.2 (2.9-13.5). Among 516 Fontan survivors, 427 (83%) enrolled in this follow-up study (Fontan 2) at 18.4 ± 3.4 years of age. Although mean scores on functional health status questionnaires were lower than the general population, individual scores were within the normal range in 78% and 88% of subjects for the Child Health Questionnaire physical and psychosocial summary score, and 97% and 91% for the SF-36 physical and mental aggregate score, respectively. Since Fontan surgery, 119 (28%) had additional cardiac surgery; 55% of these (n = 66) in the interim between Fontan 1 and Fontan 2. A catheter intervention occurred in 242 (57%); 32% of these (n = 78) after Fontan 1. Arrhythmia requiring treatment developed in 118 (28%) after Fontan surgery; 58% of these (n = 68) since Fontan 1. CONCLUSIONS: We found 95% interim transplant-free survival for Fontan survivors over an average of 7 years of follow-up. Continued longitudinal investigation into adulthood is necessary to better understand the determinants of long-term outcomes and to improve functional health status.
OBJECTIVE: Multicenter longitudinal outcome data for Fontan patients surviving into adulthood are lacking. The aim of this study was to better understand contemporary outcomes in Fontan survivors by collecting follow-up data in a previously well-characterized cohort. DESIGN: Baseline data from the Fontan Cross-Sectional Study (Fontan 1) were previously obtained in 546 Fontan survivors aged 11.9 ± 3.4 years. We assessed current transplant-free survival status in all subjects 6.8 ± 0.4 years after the Fontan 1 study. Anatomic, clinical, and surgical data were collected along with socioeconomic status and access to health care. RESULTS: Thirty subjects (5%) died or underwent transplantation since Fontan 1. Subjects with both an elevated (>21 pg/mL) brain natriuretic peptide and a low Child Health Questionnaire physical summary score (<44) measured at Fontan 1 were significantly more likely to die or undergo transplant than the remainder, with a hazard ratio of 6.2 (2.9-13.5). Among 516 Fontan survivors, 427 (83%) enrolled in this follow-up study (Fontan 2) at 18.4 ± 3.4 years of age. Although mean scores on functional health status questionnaires were lower than the general population, individual scores were within the normal range in 78% and 88% of subjects for the Child Health Questionnaire physical and psychosocial summary score, and 97% and 91% for the SF-36 physical and mental aggregate score, respectively. Since Fontan surgery, 119 (28%) had additional cardiac surgery; 55% of these (n = 66) in the interim between Fontan 1 and Fontan 2. A catheter intervention occurred in 242 (57%); 32% of these (n = 78) after Fontan 1. Arrhythmia requiring treatment developed in 118 (28%) after Fontan surgery; 58% of these (n = 68) since Fontan 1. CONCLUSIONS: We found 95% interim transplant-free survival for Fontan survivors over an average of 7 years of follow-up. Continued longitudinal investigation into adulthood is necessary to better understand the determinants of long-term outcomes and to improve functional health status.
Authors: Eva Goossens; Ine Stephani; Deborah Hilderson; Marc Gewillig; Werner Budts; Kristien Van Deyk; Philip Moons Journal: J Am Coll Cardiol Date: 2011-06-07 Impact factor: 24.094
Authors: Andrew M Atz; Thomas G Travison; Brian W McCrindle; Lynn Mahony; Michael Quartermain; Richard V Williams; Roger E Breitbart; Minmin Lu; Elizabeth Radojewski; Renee Margossian; Wesley Covitz; Welton M Gersony Journal: J Am Coll Cardiol Date: 2011-06-14 Impact factor: 24.094
Authors: Page A W Anderson; Roger E Breitbart; Brian W McCrindle; Lynn A Sleeper; Andrew M Atz; Daphne T Hsu; Minmin Lu; Renee Margossian; Richard V Williams Journal: Pediatr Cardiol Date: 2010-10-12 Impact factor: 1.655
Authors: Linda M Lambert; L LuAnn Minich; Jane W Newburger; Minmin Lu; Victoria L Pemberton; Ellen A McGrath; Andrew M Atz; Mingfen Xu; Elizabeth Radojewski; Darlene Servedio; Brian W McCrindle Journal: Pediatrics Date: 2009-10-19 Impact factor: 7.124
Authors: Lars Idorn; Annette S Jensen; Klaus Juul; Dorthe Overgaard; Niels P Nielsen; Keld Sørensen; Jesper I Reimers; Lars Søndergaard Journal: Int J Cardiol Date: 2013-04-28 Impact factor: 4.164
Authors: David M Biko; Aaron G DeWitt; Erin M Pinto; Rodney E Morrison; Jordan A Johnstone; Heather Griffis; Michael L O'Byrne; Mark A Fogel; Matthew A Harris; Sara L Partington; Kevin K Whitehead; David Saul; David J Goldberg; Jack Rychik; Andrew C Glatz; Matthew J Gillespie; Jonathan J Rome; Yoav Dori Journal: Radiology Date: 2019-04-02 Impact factor: 11.105
Authors: Max E Godfrey; Rahul H Rathod; Ellen Keenan; Kimberlee Gauvreau; Andrew J Powell; Tal Geva; Ashwin Prakash Journal: Pediatr Cardiol Date: 2018-02-05 Impact factor: 1.655
Authors: Linda M Lambert; Brian W McCrindle; Victoria L Pemberton; Danielle Hollenbeck-Pringle; Andrew M Atz; Chitra Ravishankar; M Jay Campbell; Carolyn Dunbar-Masterson; Karen Uzark; Martha Rolland; Felicia L Trachtenberg; Shaji C Menon Journal: Am Heart J Date: 2020-04-04 Impact factor: 4.749
Authors: Karen Uzark; Victor Zak; Peter Shrader; Brian W McCrindle; Elizabeth Radojewski; James W Varni; Kaitlyn Daniels; Jill Handisides; Kevin D Hill; Linda M Lambert; Renee Margossian; Victoria L Pemberton; Wyman W Lai; Andrew M Atz Journal: J Pediatr Date: 2015-12-10 Impact factor: 4.406
Authors: David J Goldberg; Victor Zak; Brian W McCrindle; Hua Ni; Russell Gongwer; Jonathan Rhodes; Robert P Garofano; Jonathan R Kaltman; Linda M Lambert; Lynn Mahony; Renee Margossian; Zebulon Z Spector; Richard V Williams; Andrew M Atz; Stephen M Paridon Journal: Pediatr Cardiol Date: 2020-09-25 Impact factor: 1.655
Authors: Anita Saraf; Christine De Staercke; Ian Everitt; Alice Haouzi; Yi-An Ko; Staci Jennings; Jonathan H Kim; Fred H Rodriguez; Andreas P Kalogeropoulos; Arshed Quyyumi; Wendy Book Journal: Int J Cardiol Date: 2020-01-09 Impact factor: 4.164
Authors: Andrew M Atz; Victor Zak; Lynn Mahony; Karen Uzark; Nicholas D'agincourt; David J Goldberg; Richard V Williams; Roger E Breitbart; Steven D Colan; Kristin M Burns; Renee Margossian; Heather T Henderson; Rosalind Korsin; Bradley S Marino; Kaitlyn Daniels; Brian W McCrindle Journal: J Am Coll Cardiol Date: 2017-06-06 Impact factor: 24.094